Publishing research using ab205921? Please let us know so that we can cite the reference in this datasheet.

ab205921 has been referenced in 36 publications.

  • Miyazaki T  et al. Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome. J Neurooncol N/A:N/A (2017). IHC ; Human . PubMed: 28447277
  • Gambichler T  et al. Expression of PD-L1 in keratoacanthoma and different stages of progression in cutaneous squamous cell carcinoma. Cancer Immunol Immunother N/A:N/A (2017). PubMed: 28501937
  • Zhu J  et al. Clinical Significance of Programmed Death Ligand-1 and Intra-Tumoral CD8+ T Lymphocytes in Ovarian Carcinosarcoma. PLoS One 12:e0170879 (2017). IHC-P ; Human . PubMed: 28125702
  • Amaya CN  et al. Enhanced expression of Programmed cell death 1 (PD-1) protein in benign vascular anomalies. Pathology 49:292-296 (2017). IHC-P ; Human . PubMed: 28238417
  • Chen S  et al. PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy. Int J Cancer 140:1384-1395 (2017). IHC-P ; Human . PubMed: 27925176
  • Jiao S  et al. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. Clin Cancer Res N/A:N/A (2017). PubMed: 28167507
  • Badros A  et al. Pembrolizumab, pomalidomide and low dose dexamethasone for relapsed/refractory multiple myeloma. Blood N/A:N/A (2017). IHC ; Human . PubMed: 28461396
  • Moon EK  et al. The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System. Ann Am Thorac Soc N/A:N/A (2017). PubMed: 28613923
  • Sato Y  et al. The PD-1/PD-L1 axis may be aberrantly activated in occupational cholangiocarcinoma. Pathol Int N/A:N/A (2017). IHC-P, IF ; Human . PubMed: 28139862
  • Rimm DL  et al. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer. JAMA Oncol N/A:N/A (2017). IHC ; Human . PubMed: 28278348
  • He Y  et al. PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes. Med Sci Monit 23:1208-1216 (2017). IHC ; Human . PubMed: 28275222
  • Lazzari C  et al. SECOND-LINE THERAPY OF SQUAMOUS NON-SMALL CELL LUNG CANCER: AN EVOLVING LANDSCAPE. Expert Rev Respir Med N/A:N/A (2017). PubMed: 28467720
  • Pai SI & Faquin WC Programmed cell death ligand 1 as a biomarker in head and neck cancer. Cancer N/A:N/A (2017). PubMed: 28472542
  • Ács B  et al. PD-1, PD-L1 and CTLA-4 in pregnancy-related - and in early-onset breast cancer: A comparative study. Breast 35:69-77 (2017). IHC ; Human . PubMed: 28651116
  • Brunnström H  et al. PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability. Mod Pathol N/A:N/A (2017). IHC ; Human . PubMed: 28664936
  • Fan Y  et al. Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors. Onco Targets Ther 9:6075-6082 (2016). IHC ; Human . PubMed: 27785054
  • Connor AA  et al. Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma. JAMA Oncol N/A:N/A (2016). IHC-P ; Human . PubMed: 27768182
  • Adam J  et al. [PD-L1 expression: An emerging biomarker in non-small cell lung cancer]. Ann Pathol N/A:N/A (2016). PubMed: 26778219
  • Lim SH  et al. Pembrolizumab for the treatment of non-small cell lung cancer. Expert Opin Biol Ther N/A:N/A (2016). PubMed: 26800463
  • Lee L  et al. Immune Checkpoint inhibitors: An introduction to the next-generation cancer immunotherapy. J Clin Pharmacol 56:157-69 (2016). IHC ; Human . PubMed: 26183909
  • Sun WY  et al. Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies. J Transl Med 14:173 (2016). IHC ; Human . PubMed: 27286842
  • Califano R  et al. Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer. Curr Oncol Rep 18:59 (2016). PubMed: 27484062
  • Hutarew G PD-L1 testing, fit for routine evaluation? From a patholo?gist's point of view. Memo 9:201-206 (2016). IHC ; Human . PubMed: 28058063
  • Phillips T  et al. Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non-Small Cell Lung Cancer. Appl Immunohistochem Mol Morphol N/A:N/A (2015). IHC ; Human . PubMed: 26317305
  • Motzer RJ  et al. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol 33:1430-7 (2015). Human . PubMed: 25452452
  • D'Angelo SP  et al. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol 46:357-65 (2015). IHC-P, IHC ; Human . PubMed: 25540867
  • Gettinger SN  et al. Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 33:2004-12 (2015). Human . PubMed: 25897158
  • Brahmer J  et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 373:123-135 (2015). IHC-P, IHC ; Human . PubMed: 26028407
  • Rizvi NA  et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 16:257-65 (2015). Human . PubMed: 25704439
  • Weber JS  et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16:375-84 (2015). Human . PubMed: 25795410
  • Robert C  et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320-30 (2015). Human . PubMed: 25399552
  • Larkin J  et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 373:23-34 (2015). Human . PubMed: 26027431
  • Postow MA  et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372:2006-17 (2015). Human . PubMed: 25891304
  • Gibney GT  et al. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res 21:712-20 (2015). Human . PubMed: 25524312
  • Wolchok JD  et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122-33 (2013). Human . PubMed: 23724867
  • Weber JS  et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol 31:4311-8 (2013). Human . PubMed: 24145345

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up